Virmani R

Virginia Commonwealth University

1
Publications in this database

PubMed name variants: Virmani R. Uses the same surname-and-first-initial grouping as the researcher table; matches are not verified identities.

183
Career-wide h-index · OpenAlex
(142,323 citations, 1768 total works)

Career-wide Research Topics · OpenAlex

Topic counts cover the OpenAlex author’s full publication record, across all conditions.

Coronary Interventions and Diagnostics (913)Cardiac Imaging and Diagnostics (667)Atherosclerosis and Cardiovascular Diseases (353)Cerebrovascular and Carotid Artery Diseases (261)Acute Myocardial Infarction Research (210)

Erythromelalgia Publications

Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist.

Kuipers RS, Kok L, Virmani R, Tefferi A
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation •

Essential thrombocytosis (ET) is a rare haematological malignancy, with an incidence rate of 1.5-2.5/100,000 per year. For many patients with ET the first manifestation of their underlying disease is a thrombotic or haemorrhagic complication. A recent retrospective study revealed an incidence rate of at least 2.1% in people under 40 years presenting with an acute coronary syndrome, although the diagnosis was initially missed in all cases. Thus, cardiologists face a much higher than average incidence rate of ET in their daily practice, but seem insufficiently aware of the disease. The current review summarises symptoms, (differential) diagnosis, complications and treatment considerations of ET of relevance for a cardiologist. Typical symptoms, besides thrombosis and haemorrhage, include erythromelalgia and aquagenic pruritus, while platelets > 450 × 10/l are a diagnostic for ET once other myeloproliferative neoplasms, secondary and spurious thrombocytosis have been excluded. With regard to treatment, timing of revascularisation depends on the presence of ischaemia and concurrent platelet counts. In the presence of ischaemia, revascularisation should not be delayed and adequate platelet counts can be achieved by platelet apheresis. In the absence of ischaemia, revascularisation can be delayed until adequate platelet counts have been achieved by cytoreductive therapies. Cardiologists should be aware of/screen for possible ET.